Christos Tsaklakidis

This inventor holds 59 USPTO granted patents and 2 published patent applications, plus 8 CIPO patents and 22 EPO patents, primarily in Pharmaceutical Chemistry (CPC class C07D). Top assignees: Merck Patent Gmbh, Boehringer Mannheim Gmbh, Merck Patent Gesellschaft MIT Beschrankter Haftung. Active years: 1990-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Christos Tsaklakidis. Retrieved from https://idiyas.com/inventor/christos-tsaklakidis

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 59 (Patent Applications = 2)

% Patents Active = 37.3

CIPO Patents = 8 (Patent Applications = 4)

EPO Patents = 22 (Patent Applications = 15)

Average Co-Inventor Count = 4.2

ph-index = 6

Forward Citations = 126(Granted Patents)

Forward Citations (Not Self Cited) = 120(Dec 10, 2025)

Inventors with similar research interests:

Company Filing History:

Boehringer Mannheim Gmbh

patents

5 out of 1,248

Merck Patent Gesellschaft MIT Beschrankter Haftung

patents

4. 1 out of 121

Merck Patent Gesellschaft

patents

5. 1 out of 488

Roche Diagnostics Gmbh

patents

6. 1 out of 834,513

Other

patents

Years Active: 1990-2025

Loading Chart...

Areas of Expertise:

Heterocylic Derivatives

Cyclopentylamine Derivatives

FASN Inhibitors

SGLT Inhibitors

Factor Xa Inhibitors

Thromboembolic Diseases

Aminostatin Derivatives

Quinolin Derivatives

Hydroxystatin Derivatives

Indolizine Derivatives

Carbonyl Compounds

Prolinyl Derivatives

59 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12371430 - 5-morpholin-4-yl-pyrazolo[4,3-b]pyridine derivatives (2025-07-29),

2. 11939314 - Quinolin-2-one derivatives (2024-03-26),

3. 11186562 - Quinolin-2-one derivatives (2021-11-30),

4. 11174241 - Quinolin-2-one derivatives (2021-11-16),

5. 10669251 - Quinolin-2-one derivatives (2020-06-02),

6. 10570149 - Tricyclic heterocylic derivatives (2020-02-25),

7. 10118919 - 3-substituted cyclopentylamine derivatives (2018-11-06),

8. 10077288 - Hydroxystatin derivatives for the treatment of arthrosis (2018-09-18),

9. 9884814 - Acylguanidines for treating osteoarthritis (2018-02-06),

10. 9839665 - Aminostatin derivatives for the treatment of arthrosis (2017-12-12),

11. 9809552 - Piperazine derivatives as FASN inhibitors (2017-11-07),

12. 9790216 - 3-substituted cyclopentylamine derivatives (2017-10-17),

13. 9732032 - 3-aminocyclopentane carboxamide derivatives (2017-08-15),

14. 9718785 - 1,3-Disubstituted cyclopentane derivatives (2017-08-01),

15. 9670142 - 1,3-diaminocyclopentane carboxamide derivatives (2017-06-06),

Title: The Inventive Journey of Christos Tsaklakidis

Introduction: Christos Tsaklakidis, based in Weinheim, Germany, is an accomplished inventor with an impressive portfolio of 58 patents. He has significantly contributed to the field of medicinal chemistry and cancer treatment through his innovative research and development of quinolin-2-one derivatives.

Latest Patents: Among his latest inventions are quinolin-2-one derivatives, which are compounds that serve as inhibitors of c-Kit kinase. These compounds, outlined in the patent claims, possess the potential to be employed in the treatment of cancer, showcasing the importance of his work in the ongoing battle against this disease.

Career Highlights: Christos Tsaklakidis has held notable positions in esteemed companies such as Merck Patent GmbH and Boehringer Mannheim GmbH. His work within these organizations has allowed him to push the boundaries of research and innovation in the pharmaceutical industry.

Collaborations: Throughout his career, Tsaklakidis has had the privilege of collaborating with talented colleagues, including Dieter Dorsch and Werner Mederski. These collaborations have furthered his research endeavors and led to significant advancements in the fields of medicine and chemistry.

Conclusion: Christos Tsaklakidis continues to make strides in the world of inventions, particularly in cancer research. His dedication to innovation, combined with his extensive patent portfolio, positions him as a prominent figure in the realm of medicinal chemistry. As he advances his research, the potential impact of his work on the treatment of cancer remains promising.

Profile summary based on public USPTO records.